Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.

Gilead isn’t giving details about the events behind the partial hold on magrolimab/Vidaza combination studies, but analysts suspect cytopenias are the culprit.

Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.

GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.